Oxford Catalysts Announces Major Lab Expansion
News Jan 30, 2008
Oxford Catalysts has announced that it is expanding its laboratory facilities and investing in additional analytical equipment in order to accelerate its catalyst development and serve its growing customer base.
The expansion, due to begin at the end of January 2008, will involve a total investment of over £1 million, and will more than double the floor space of the existing laboratory facilities.
As part of the project, Oxford Catalysts has already purchased two Amtec Spider16 high throughput screening gas phase reactor systems. These are due to be brought into operation in March and April 2008.
To supplement the rigs it already owns, it also plans to purchase three additional rigs, including a small scale Fischer-Tropsch (FT) rig, a reforming test rig, and a hydro-desulphurization test rig, along with associated analytical and catalyst preparation equipment.
In addition, Oxford Catalysts will be taking on the necessary technicians and catalyst preparation chemists needed to support the new equipment, as well as employing additional senior technology managers. In all, scientific staff numbers are expected to rise from the current 15 to around 23.
The expansion is expected to be completed by July 2008. In the meantime, Oxford Catalysts will be posting regular progress updates on its website.
Derek Atkinson, Business Development Director, Oxford Catalysts says: “Developing new catalysts can be a time consuming process, and each catalyst has to be custom-made for a particular application to suit a customer's requirements. Having this expanded lab facility will allow us to carry out the necessary testing to provide our customers with the essential information they need about a catalyst more quickly. It will also help Oxford Catalysts to develop further new and innovative catalysts at a rate that will allow us to meet demand for new applications within the clean fuels area as they continue to arise."
AIDS Vaccine Design: New Data Offers Important InsightNews
New data published in Immunity further illuminate how some human beings generate powerful, HIV-blocking antibodies. The results offer important insight into a potential AIDS vaccine design.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE